Open Nav

Please submit your session questions in advance at

Senti Biosciences

  • Timothy Lu, Senti Biosciences

Founded in 2016 by Drs. Timothy Lu, Philip Lee, Jim Collins and Wilson Wong, Senti Biosciences is the next generation therapeutics company that designs gene circuits and programs cells for tremendous therapeutic value. Senti's mission is to engineer an entirely new class of medicine that will transform people’s lives by curing the most complex diseases. Backed by a syndicate of leading biotech and tech investors including NEA, 8VC, Lux, Pear, Menlo Ventures, and Amgen Ventures, and led by an experienced team with deep translational knowledge of advanced cell therapies, the company is leveraging its proprietary gene circuit repertoire to solve the most pressing unmet needs in oncology and other difficult disease areas.

  • Date:Tuesday, February 12
  • Time:1:30 PM - 1:45 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23526
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Connect with investors, potential partners, peers
  • Company Website:
  • Company HQ City:South San Francisco
  • Company HQ State:California
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$53 million
  • Previous and Current Investors:NEA, 8VC, Lux, Menlo Ventures, Amgen Ventures, Omega Funds, Allen & Co, Pear
  • CEO/Top Company Official:Timothy Lu
  • Year Founded:2016
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:Immunomodulatory gene-modified cell therapy
  • Development Phase of Primary Product:Pre-Clinical
Timothy Lu
Senti Biosciences